Clinical trial

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular…

NCT00243178 · Sanofi, Industry · Terminated

Key facts

NCT number NCT00243178
Title Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)
Official title A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation
Lead sponsor Sanofi, Industry
Collaborators Bristol-Myers Squibb Industry
Status Terminated
Phase Phase 3
Study type Interventional
Conditions Atrial Fibrillation, Vascular Risk
Intervention type Drug
Interventions clopidogrel (SR25990C)
Enrollment 6,706
Start date Jul 1, 2003
Primary completion Sep 1, 2005
Completion Sep 1, 2005
First posted Oct 21, 2005
Last update posted Oct 19, 2009
Countries Australia, Austria, Belgium, Brazil, Canada, Chile, Czechia, Denmark, Finland, France, Germany, Greece and 20 more

At a glance

  • 10–99 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies